# Santaris Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/santaris-pharma

- Industry: Biotechnology
- Headquarters: Denmark
- Website: www.santaris.com
- Total disclosed funding: $35M
- Latest round: Series C (Dec 18, 2007)
- Investors on record: 13

## About

Santaris Pharma is a biotechnology company specializing in developing innovative therapies based on RNA-targeted technology to address unmet medical needs in various diseases.Founded in 2003, Santaris Pharma focuses on RNA-targeted therapies. The company was acquired by Roche in August 2014 for USD 450 mn. Santaris Pharma operates out of Denmark, expanding its capabilities in the biotech sector.Santaris Pharma develops RNA-targeted therapeutics aimed at treating diseases through innovative mechanisms. The company’s pipeline includes candidates designed for oncology and other therapeutic areas, utilizing proprietary technologies to target disease-causing genes effectively.In 2018, Santaris Pharma reported a revenue of USD 31.47 mn and an EBITDA of USD 26.61 mn, reflecting its strong performance within the biotechnology sector.Following its acquisition by Roche, Santaris Pharma is expected to leverage resources for the development of new RNA-targeted products. The focus includes expanding into new markets, particularly in North America and Europe, with plans to enhance their product pipeline in the coming years.

## Funding rounds

- Series C, Dec 18, 2007, $30M — Global Life Science Ventures, Seventure Partners, Gilde Healthcare, Innovation Capital, Forbion, Heartcore Capital, Omega Asset Management, BankInvest, Novo Holdings
- Series B, Jun 29, 2005, $5.3M — InnovationsKapital, DKA Capital, Dansk Erhvervsinvestering, LD Pensions, BankInvest, Novo Holdings

## Investors

- InnovationsKapital (https://capitalatlas.ai/funds/innovationskapital) — Series B
- DKA Capital (https://capitalatlas.ai/funds/dka-capital) — Series B
- Dansk Erhvervsinvestering (https://capitalatlas.ai/funds/dansk-erhvervsinvestering) — Series B
- LD Pensions — Series B
- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series B, Series C
- Novo Holdings — Series B, Series C
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series C
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C
- Innovation Capital — Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series C
- Omega Asset Management (https://capitalatlas.ai/funds/omega-asset-management) — Series C